Sign In
Buy ETNB
$14.84
+0 (+0%)
At Close: Jan 29, 2026
89bio (ETNB) Receives a Buy from Oppenheimer
09:34pm, Monday, 13'th Apr 2020
In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on 89bio (ETNB), with a price target of $60.00. The company's shares closed
89bio (ETNB) Receives a Buy from Oppenheimer
09:34pm, Monday, 13'th Apr 2020
In a report released today,
Jay Olson
from Oppenheimer maintained a
Buy
rating on 89bio (
ETNB
–
Research Report
), with a price target of
$60.00
. The company’s shares closed last Monday at $20.9
SAN FRANCISCO, April 13, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the tre
89bio (NASDAQ:ETNB) Lowered to Hold at Zacks Investment Research
07:20am, Saturday, 11'th Apr 2020
Zacks Investment Research lowered shares of 89bio (NASDAQ:ETNB) from a buy rating to a hold rating in a report released on Tuesday morning, Zacks.com reports. According to Zacks, “89bio Inc. is clin
Akero Heads to Top of Class in NASH; Genfit Says Pandemic Won’t Delay Data
04:02pm, Friday, 10'th Apr 2020
Akero’s FGF21 analog yields 63 percent to 72 percent relative hepatic fat reduction in Phase 2a study; the company awaits biopsy data hoping to see a
Zacks Investment Research Upgrades 89bio (NASDAQ:ETNB) to "Buy"
06:02am, Wednesday, 08'th Apr 2020
89bio (NASDAQ:ETNB) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Monday, Zacks.com reports. The brokerage presentl
89bio (ETNB) Gets a Buy Rating from Oppenheimer
11:05am, Wednesday, 01'st Apr 2020
Oppenheimer analyst Jay Olson maintained a Buy rating on 89bio (ETNB) today and set a price target of $60.00. The company's shares closed last Tuesday at
89bio (ETNB) Gets a Buy Rating from Oppenheimer
11:05am, Wednesday, 01'st Apr 2020
Oppenheimer analyst Jay Olson maintained a Buy rating on 89bio (ETNB – Research Report) today and set a price target
89bio Appoints Healthcare Industry Veteran Steven Altschuler, M.D., as Chairman of the Board of Directors
08:05pm, Wednesday, 25'th Mar 2020
SAN FRANCISCO, March 25, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the trea
89bio (ETNB) Gets a Buy Rating from Oppenheimer
01:26am, Thursday, 19'th Mar 2020
Oppenheimer analyst Jay Olson maintained a Buy rating on 89bio (ETNB) yesterday. The company's shares closed last Monday at $17.35, close to its 52-week
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
12:00am, Thursday, 19'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 18)
Biomerica, Inc. (NASDAQ...
89bio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
08:05pm, Wednesday, 18'th Mar 2020
- BIO89-100 Phase 1b/2a NASH study on track for topline data in 2H20 - - Initiation of Phase 2 SHTG study planned in 1H20 - SAN FRANCISCO, March 18, 2020 -- 89bio, Inc..
The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19
01:05pm, Thursday, 05'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 4) * 89bio Inc (NASDAQ: ETNB) * Arcus Biosciences In
89bio to Present at the SVB Leerink 9th Annual Global Healthcare Conference
09:05pm, Friday, 21'st Feb 2020
SAN FRANCISCO, Feb. 21, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treat
Will 89bio (NASDAQ:ETNB) Spend Its Cash Wisely?
11:43am, Tuesday, 11'th Feb 2020
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
